Multidisciplinary Authorship Among Infectious Diseases Society of America Clinical Practice Guidelines: Examining the Contributions of Infectious Diseases Pharmacists

Freeman, Lauren K; Lindsay, Jasmine N; Davis, Sarah E.; Norman, Brian F; Thompkins, April W; Luther, Vera; Ohl, Christopher; Bookstaver, P Brandon

doi:10.1093/ofid/ofy287

Cited by 6 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall proportion of pharmacist authorship is 40% in this cohort of guidelines published from 2012 to 2016, which was higher than anticipated by the authors. By comparison, in another study by these investigators, pharmacist authorship among current Infectious Diseases Society of America (IDSA) guidelines was reported at 21% . Because the present study includes such a narrow scope of guidelines intended for pharmacists and with significant pharmacotherapeutic recommendations, pharmacist authorship could have been much higher.…”

Section: Discussioncontrasting

confidence: 57%

“…Others have recently included pharmacists as part of CPG expert panels, such as the IDSA on Clostridium difficile infection management and the American Academy of Family Physicians on the Eighth Joint National Committee management of high blood pressure . While pharmacists have had some involvement in the creation of CPGs since the NAM recommendations in 2011, pharmacist input is still not well utilized in the majority of national guidelines . High impact CPGs, such as “Surviving Sepsis Guidelines for Management of Sepsis and Septic Shock” and “Kidney Disease: Improving Global Outcomes Management of Blood Pressure in Chronic Kidney Disease” lack pharmacist authorship despite heavy discussion and numerous pharmacotherapeutic recomendations .…”

Section: Discussionmentioning

confidence: 99%

“…A previous study conducted by these investigators concluded that there were no differences in the rate of pharmacist authorship between the updated IDSA guidelines published after the NAM recommendations compared with the previous IDSA guidelines published prior to NAM recommendations. Despite these recommendations stating that guideline panels should be multidisciplinary, the trend of pharmacist authorship relating to pharmacotherapeutic guideline recommendations has not changed …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacist authorship on clinical practice guidelines

Thompkins

Norman

Hill

et al. 2018

J Am Coll Clin Pharm

Self Cite

View full text Add to dashboard Cite

Introduction The National Academy of Medicine (NAM; formerly the Institute of Medicine) recommends multidisciplinary authorship as a standard for developing trustworthy guideline panels. The purpose of this study is to describe pharmacist authorship on clinical practice guideline (CPG) expert panels. Methods Guidelines published between January 1, 2010 and December 31, 2016 and were available in the Agency for Healthcare Research and Quality National Guideline Clearinghouse database were eligible for study inclusion. Only guidelines with pharmacotherapeutic recommendations were included. The primary end point was the proportion of pharmacist authorship on national CPGs. Pharmacist authorship by specialty area and characteristics of pharmacist authors were described. Results Of the 143 guidelines included, 58 (40.6%) had at least one pharmacist author. Guidelines developed by the Veterans Affairs/Department of Defense (VA/DoD; n = 7) and the Clinical Pharmacogenetics Implementation Consortium (CPIC; n = 13) always included at least one pharmacist. Excluding VA/DoD and CPIC guidelines, the proportion of pharmacist authorship was 30.9% (38/123). A pharmacist served as the first, senior, and/or corresponding author on 19% (27/143) of CPGs. There were 1919 total authors with an average of 13.4 (+7.4) authors per guideline. Pharmacists represented 6.8% (130/1919) of all authors, and 83 were unique pharmacist authors. Critical care, emergency medicine, and adult internal medicine guidelines had the largest proportion of pharmacist authorship, while oncology and pediatric guidelines had the smallest. Pharmacy organizations sponsored or endorsed 5.2% (3/58) of CPGs with a pharmacist author. Conclusion The majority of CPGs in this cohort did not include a pharmacist in the authorship and when included, was often limited to a single pharmacist. It is imperative for pharmacy organizations to collaborate with sponsoring medical organizations and position clinical pharmacists to serve as expert members on CPGs consistent with NAM recommendations.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacist authorship on clinical practice guidelines

Thompkins

Norman

Hill

et al. 2018

J Am Coll Clin Pharm

Self Cite

View full text Add to dashboard Cite

show abstract

“…Unsurprisingly, only one author of the ACG CPG has an infectious diseases background and only one author of the IDSA/SHEA CPG has a gastroenterology background. The authors of each CPG are represented by both physicians and pharmacists, which provides a value-added expert level review [ 15 , 16 ].…”

Section: Guideline Highlightsmentioning

confidence: 99%

Is Three Company or a Crowd? Comparing and Contrasting U.S. and European Clostridioidesdifficile Clinical Practice Guidelines

et al. 2022

Self Cite

View full text Add to dashboard Cite

In 2021, the American College of Gastroenterology (ACG), the Infectious Diseases Society of America in conjunction with the Society for Healthcare Epidemiology of America (IDSA/SHEA), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published updated clinical practice guidelines (CPGs) for the management of Clostridioides difficile infections. The differences, sometimes subtle, between these guideline recommendations have caused some debate among clinicians. This paper delves into select key recommendations from each respective CPG and analyzes the differences and evidence associated with each. One primary difference between the CPGs is the preference given to fidaxomicin over vancomycin for initial treatment in non-severe and severe disease endorsed by IDSA/SHEA and ESCMID guidelines, while the ACG-sponsored CPGs do not offer a preference. The emphasis on cost effective data was also a noticeable difference between the CPGs and thus interpretation of the available evidence. When using guidelines to help support local practice or institutional treatment pathways, clinicians should carefully balance CPG recommendations with local patient populations and feasibility of implementation, especially when multiple guidelines for the same disease state exist.

show abstract

“…Although the medical literature increases by thousands of articles each day, many clinical controversies still persist or are recognized after initial, single‐center data are published. Pharmacists offer unique perspectives to clinical research and are more commonly being recognized as thought leaders in many areas of clinical research and practice . Pharmacists may desire to participate or lead clinical research efforts for a variety of reasons.…”

Section: Introductionmentioning

confidence: 99%

How‐to guide for effectively performing and coordinating multicenter observational research as a clinical pharmacist

Hammond¹,

Rech

2019

J Am Coll Clin Pharm

View full text Add to dashboard Cite

While single‐center research serves multiple purposes for the provision of patient care and identification of testable hypotheses, the importance of multicenter research is well established. The purpose of this “how‐to” guide is to assist pharmacists with the various steps in performing and coordinating multicenter, observational research. The steps that are reviewed include identifying a precise and appropriate research question; determining the expected final products or deliverables from the project and the timeline needed to satisfactorily achieve each step in the process toward these deliverables; establishing the research team structure and recognition of project contributions; navigating the institutional review board approval and data sharing and storage processes; collecting, cleaning, and analyzing data; evaluating additional project management considerations; avoiding and resolving pitfalls of multicenter research; and wrapping up the project. Resources are provided to encourage and support pharmacist principal investigators in their research efforts.

show abstract

Multidisciplinary Authorship Among Infectious Diseases Society of America Clinical Practice Guidelines: Examining the Contributions of Infectious Diseases Pharmacists

Cited by 6 publications

References 13 publications

Pharmacist authorship on clinical practice guidelines

Pharmacist authorship on clinical practice guidelines

Is Three Company or a Crowd? Comparing and Contrasting U.S. and European Clostridioidesdifficile Clinical Practice Guidelines

How‐to guide for effectively performing and coordinating multicenter observational research as a clinical pharmacist

Contact Info

Product

Resources

About